Mandate

Vinge advises Edgeware AB (publ) in connection with listing on Nasdaq Stockholm

December 14, 2016

 Vinge has advised Edgeware AB (publ) (“Edgeware”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on 29 November 2016 and the first day of trading on Nasdaq was 9 December 2016. The offer price was set at SEK 29 per share, which corresponded to a market value for the total number of shares in the company of approximately MSEK 870. The total value of the offering amounted to MSEK 450 provided an overallotment option was exercised in its entirety.
 
Edgeware was founded in 2004 and has since evolved into a global, high-tech company that develops and offers hardware and software systems as well as associated services that enable effective and scalable TV and video streaming over IP. The Company’s solutions are primarily sold to telecom and cable operators as well as broadcasters and content owners that want to efficiently, securely and cost-efficiently make TV and video content available to their viewers.
 
Vinge’s team primarily consisted of Johan Larsson, Jesper Schönbeck, Rikard Lindahl, Johan Mattson, Amanda Knutsson, Malte Hedlund and Michaela Cronemyr. Tora Hansjons, Emilie Parland and Maria Schultzberg advised on tax issues.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025